Citigroup
IKT icon

Citigroup’s Inhibikase Therapeutics IKT Stock Holding History

Citigroup’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.45K Buy
5,032
+1,746
+53% +$3.1K ﹤0.01% 5102
2025
Q4 		$6.74K Buy
3,286
+2,384
+264% +$3.79K ﹤0.01% 5171
2025
Q3 		$1.46K Sell
902
-19,491
-96% -$33.8K ﹤0.01% 5558
2025
Q2 		$39.8K Sell
20,393
-5,372
-21% -$10.5K ﹤0.01% 4881
2025
Q1 		$56.4K Sell
25,765
-51,335
-67% -$129K ﹤0.01% 4846
2024
Q4 		$251K Buy
+77,100
New +$192K ﹤0.01% 4273
2022
Q3 		– Sell
-83
Closed – – 6061
2022
Q2 		$0 Buy
+83
New +$490 ﹤0.01% 6419

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citigroup's IKT Position: Q1 2026 in Review

Citigroup increased its Inhibikase Therapeutics (IKT) stake by 53% in Q1 2026, buying an estimated $3.1K and bringing the position to 5,032 shares worth $8.45K. The position accounts for ﹤0.01% of the portfolio, ranked #5102.

Citigroup first reported a position in IKT in Q2 2022 and has held it in 7 quarters since. The position peaked at $251K in Q4 2024. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Citigroup held 5,032 shares of Inhibikase Therapeutics worth $8.45K as of Q1 2026.
  • Citigroup bought 1,746 Inhibikase Therapeutics shares in Q1 2026, an estimated $3.1K.
  • Inhibikase Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5102 holding.
  • Citigroup first reported a position in Inhibikase Therapeutics in Q2 2022 and has held it in 7 quarters since.
  • Citigroup's Inhibikase Therapeutics position peaked at $251K in Q4 2024.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.